(RTTNews) - PMV Pharmaceuticals, Inc. (PMVP), a precision oncology company focused on p53-targeting therapies, announced appointment of Philip Herman as Chief Commercial Officer (CCO) to lead commercial strategy and launch preparations for Rezatapopt.

Rezatapopt is being developed for patients with p53 Y220C mutations, a specific mutation found in multiple cancers.

Herman brings more than 24 years of experience in building commercial organizations and launching oncology and rare disease therapies.

He most recently served as Chief Commercial and Portfolio Development officer at Repare Therapeutics and previously was CCO at Y-mAbs Therapeutics, where he led the launch of DANYELZA (naxitamab) in pediatric oncology.

At PMV, Herman will oversee commercial preparations for rezatapopt, the company's investigational p53 reactivator.

The company is completing enrollment of patients on the PYNNACLE clinical trial and plans to submit a New Drug Application (NDA) seeking accelerated approval for rezatapopt in patients with platinum-resistant/refractory ovarian cancer in the first quarter of 2027.

Before joining PMV, Herman held several commercial leadership positions at Santhera Pharmaceuticals, Dyax, Vanda Pharmaceuticals and Pfizer.

PMVP closed Tuesday's trade at $1.34, up 3.88%. In the after-hours trading, the stock is up 0.75% at $1.35.